Korean Biotechs to Present Blood Cancer Data at ASH
Several South Korean firms will share clinical and preclinical blood cancer results at the ASH 2026 annual meeting in New Orleans.
Updated on Nov. 5, 2026 in Cancer
Korean biotech companies will present blood cancer data at the ASH 2026 annual meeting in New Orleans in December 2026. Curocell will share long-term follow-up for its CAR-T therapy Rimkato, while other firms will disclose early-stage trial and preclinical results.
Why it matters
The presentations offer early clinical signals for cell and antibody-drug conjugate therapies targeting blood cancers. Results at a major hematology meeting help shape how these experimental treatments are evaluated and developed.
The Rimkato follow-up covers up to 44.5 months, with a 81.6% three-year survival rate among patients who held complete remission for at least six months. Full datasets and the patient numbers behind these figures were not disclosed, and GCC2005's optimal dose remains to be determined in Phase 1b.
The players
Curocell
Curocell is a South Korean biotechnology company developing CAR-T cell therapies for blood cancers.
Verismo Therapeutics
Verismo Therapeutics is a U.S. cell therapy company and subsidiary of HLB Innovation developing CAR-T treatments.
LigaChem Biosciences
LigaChem Biosciences is a South Korean company developing antibody-drug conjugates for cancer treatment.
The details
Curocell will present Rimkato clinical results in poster form, while GC Cell will disclose Phase 1a results for GCC2005, with no dose-limiting toxicity at the highest dose level and no treatment-related serious adverse events reported. LigaChem Biosciences will present preclinical data for LCB122A, a CD33-targeting ADC, and Verismo Therapeutics, the U.S. subsidiary of HLB Innovation, will present interim Phase 1 results for CAR-T therapy SynKIR-310.
Timeline
December 2026: Korean firms present blood cancer data at the ASH 2026 annual meeting in New Orleans.
Within 2026: Curocell plans a domestic launch of Rimkato.
Market Landscape
LigaChem's preclinical claim positions LCB122A as a potential successor to Mylotarg, the approved CD33-targeting antibody-drug conjugate. The presentations at ASH 2026 show Korean developers pursuing CAR-T and ADC approaches in the competitive blood cancer treatment field.
These therapies remain in early clinical development, so patients cannot access them through standard treatment yet. Any eventual availability will depend on regulatory approval and the results of later-stage trials.
The takeaway
Early data from several Korean developers suggest CAR-T and antibody-drug conjugate approaches may broaden options for blood cancer patients. Readers should watch for full datasets and later-stage trial results before drawing firm conclusions.
What happens next
Curocell plans to proceed with a domestic launch of Rimkato within 2026, and GC Cell plans to establish the optimal GCC2005 dose through Phase 1b.
Further reading
For more on the treatments behind these data, see the Cancer section.
Source note: This article includes information reported by Business Korea.
